Background: The influence of obesity on the cardiac geometry is less clear. Our objective was to determine if body mass index (BMI) was an independent predictor of left atrial enlargement (LAE) relative to LV thicknes...Background: The influence of obesity on the cardiac geometry is less clear. Our objective was to determine if body mass index (BMI) was an independent predictor of left atrial enlargement (LAE) relative to LV thickness, dimension and function. Methods: Retrospective analysis of 90 consecutive patients with available echocardiographic data was performed. Patients were categorized into those with LAE (defined as >4.0 cm in transverse dimension by M-mode, n = 36) and those with normal LA size (n = 54). The clinical and echocardiographic variables were compared between the two groups. Results: Compared to patients with normal LA size, patients with LAE had significantly higher BMI (32 ± 8 vsi ± 8, p = 0.006), greater LV thickness, increased LV cavity dimension, and depressed LV systolic function. BMI was a strong and independent predictor of LAE. Left ventricular thickness and LV end-diastolic (LVED) dimension were other independent predictors of LAE. After adjusting for the significant effects of LV thickness and LV diameter, every unit increase in BMI resulted in an 8% increase in the odds of having LAE. Conclusions: 1) Higher BMI is an independent predictor of LAE. 2) Presence of LV enlargement and LV systolic dysfunction in these patients suggests that in the face of higher BMI, cardiac workload may exceed the compensatory LV hypertrophy and 3) LAE may be a consequence of the greater force developed by the LA to fill the LV.展开更多
目的观察厄贝沙坦对原发性高血压患者阵发性心房纤颤(PAF)及其左心房大小的影响。方法将64例原发性高血压合并PAF的患者随机分为两组,每组32例,治疗组接受厄贝沙坦150 m g/d,必要时联合利尿剂或β受体阻滞剂或钙通道阻滞剂控制血压。对...目的观察厄贝沙坦对原发性高血压患者阵发性心房纤颤(PAF)及其左心房大小的影响。方法将64例原发性高血压合并PAF的患者随机分为两组,每组32例,治疗组接受厄贝沙坦150 m g/d,必要时联合利尿剂或β受体阻滞剂或钙通道阻滞剂控制血压。对照组给予钙通道阻滞剂或(和)β受体阻滞剂或与利尿剂联合控制血压。随访6个月,测定两组治疗前、后的左心房内径(LAD)、血压及心房纤颤(AF)发作次数。结果两组均能显著降低血压,治疗组治疗后的LAD及AF发作次数较对照组显著减少(P<0.05)。结论厄贝沙坦对PAF发作有预防作用,并且可逆转左心房扩大。展开更多
文摘Background: The influence of obesity on the cardiac geometry is less clear. Our objective was to determine if body mass index (BMI) was an independent predictor of left atrial enlargement (LAE) relative to LV thickness, dimension and function. Methods: Retrospective analysis of 90 consecutive patients with available echocardiographic data was performed. Patients were categorized into those with LAE (defined as >4.0 cm in transverse dimension by M-mode, n = 36) and those with normal LA size (n = 54). The clinical and echocardiographic variables were compared between the two groups. Results: Compared to patients with normal LA size, patients with LAE had significantly higher BMI (32 ± 8 vsi ± 8, p = 0.006), greater LV thickness, increased LV cavity dimension, and depressed LV systolic function. BMI was a strong and independent predictor of LAE. Left ventricular thickness and LV end-diastolic (LVED) dimension were other independent predictors of LAE. After adjusting for the significant effects of LV thickness and LV diameter, every unit increase in BMI resulted in an 8% increase in the odds of having LAE. Conclusions: 1) Higher BMI is an independent predictor of LAE. 2) Presence of LV enlargement and LV systolic dysfunction in these patients suggests that in the face of higher BMI, cardiac workload may exceed the compensatory LV hypertrophy and 3) LAE may be a consequence of the greater force developed by the LA to fill the LV.
文摘目的观察厄贝沙坦对原发性高血压患者阵发性心房纤颤(PAF)及其左心房大小的影响。方法将64例原发性高血压合并PAF的患者随机分为两组,每组32例,治疗组接受厄贝沙坦150 m g/d,必要时联合利尿剂或β受体阻滞剂或钙通道阻滞剂控制血压。对照组给予钙通道阻滞剂或(和)β受体阻滞剂或与利尿剂联合控制血压。随访6个月,测定两组治疗前、后的左心房内径(LAD)、血压及心房纤颤(AF)发作次数。结果两组均能显著降低血压,治疗组治疗后的LAD及AF发作次数较对照组显著减少(P<0.05)。结论厄贝沙坦对PAF发作有预防作用,并且可逆转左心房扩大。
